Evolocumab's LDL Lowering Surpassed Inclisiran's in ORION-3

Results from a crossover subgroup of 92 patients in ORION-3 documented evolocumab's greater LDL-lowering efficacy compared with inclisiran.

Related Keywords

United States , New York , Chicago , Illinois , London , City Of , United Kingdom , American , Kausikk Ray , Roberts Rosenson , , Amgen , American Heart Association , Medicines Company , American College Of Cardiology , Drug Administration , Novartis , Imperial College London , Icahn School Of Medicine At Mount Sinai , Lancet Diabetes , Icahn School , Mount Sinai , American College , Expert Consensus Decision Pathway , Lipids , Ipid Management , Cv , Ardiovascular , Pcsk9 , Roprotein Convertase Subtilisin Kexin Type 9 , Biologic Therapy , Monoclonal Antibody , Etuximab , Ituximab , Medicare , Atherosclerotic Heart Disease , Therosclerotic Cardiovascular Disease , Oronary Heart Disease , Schemic Heart Disease , Cardiovascular Disease , Vd Cardiovascular Disease , Grant , Familial Hypercholesterolemia , Low Ldl Cholesterol , Ypobet ,